Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05824767 · ClinicalTrials.gov registry record · Phase 4
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
A Phase 4 study of Septic Shock and Vasodilatory Shock, sponsored by University of New Mexi.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05824767 is a Phase 4 study of Septic Shock and Vasodilatory Shock that has completed, run by University of New Mexi. The registered enrollment target is 40 participants, below the 5,057-participant average among 24 other Septic Shock trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05824767, a Phase 4 study of Septic Shock and Vasodilatory Shock, has completed, sponsored by University of New Mexi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will be a randomized controlled single-center pilot trial comparing the use of angiotensin II versus standard-of-care (SOC) vasopressor therapy in adult patients with persistent vasodilatory shock despite moderate-dose norepinephrine, with a primary outcome of the ability of novel biomarkers (renin and DPP3) to predict blood pressure response to angiotensin II. Given our angiotensin II will be compared to SOC, this will be an unblinded study.
Conditions Studied
Interventions
- DRUG Angiotensin II
Study Locations (1)
New Mexico
- University of New Mexico Health Sciences Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2025-03-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05824767
The ClinicalTrials.gov registry entry for NCT05824767 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,057-participant average among 24 other Septic Shock trials with a reported enrollment target (99% lower). The listed sponsor is University of New Mexi, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Septic Shock appearing as the primary indexed condition, and to 1 intervention - of which Angiotensin II is the first listed.
NCT05824767 reports 1 study location spanning 1 distinct geographic area - top geographies include New Mexico.
Frequently Asked Questions
What is clinical trial NCT05824767 about?
NCT05824767 is a clinical study titled "Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock". This trial will be a randomized controlled single-center pilot trial comparing the use of angiotensin II versus standard-of-care (SOC) vasopressor therapy in adult patients with persistent vasodilatory shock despite moderate-dose norepinephrine, with a primary outcome of the ability of novel biomark...
What is the current status of trial NCT05824767?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2023-04-17. Estimated completion is 2025-03-12.
What conditions does trial NCT05824767 study?
This clinical trial studies the following conditions: Septic Shock, Vasodilatory Shock.
What interventions are being tested in trial NCT05824767?
The interventions under investigation include: Angiotensin II (DRUG).
Who is sponsoring clinical trial NCT05824767?
This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05824767 being conducted?
This trial has 1 study location across New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Septic Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Early Angiotensin II in the Emergency Department
RECRUITING · Phase 4
-
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
RECRUITING · Phase 4
-
Vasopressin for Septic Shock Pragmatic Trial
ACTIVE NOT RECRUITING · Phase 4
-
Stress Hydrocortisone In Pediatric Septic Shock
RECRUITING · Phase 3
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.